Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27595694 | 1.00 | TSHR (0.40) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL16320674 | 0.77 | CTSS (0.46) | CA1CA2CA7CA9CTSS | |
| SCHEMBL4898269 | 0.76 | TSHR (0.47) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL4907937 | 0.76 | TSHR (0.47) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL4898264 | 0.76 | TSHR (0.47) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL27686748 | 0.76 | CA1 (0.62) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL8328277 | 0.76 | CA1 (0.62) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL6580596 | 0.76 | CA1 (0.62) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL3325707 | 0.76 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL1867639 | 0.76 | TSHR (0.50) | TSHRCA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138160-A1 | Preventive/therapeutic method for cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040116330-A1 | Diagnosing or specifying a growth factor receptor expressed in cancer cells, and selectively inhibiting all or a part of the growth factor receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| CN-1487936-A | Medicinal compositions having improved absorbability | ����ҩƷ��ҵ��ʽ���� | 2004-04-07 | — | — | CN | disclosed |
| US-6716863-B2 | TYROSINE KINASE INHIBITORS; ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-20040058956-A1 | Pharmaceutical composition having an improved water solubility | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| US-20040053972-A1 | Medicinal compositions having improved absorbability | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040024035-A1 | Heterocyclic compounds, their production and use | TASAKA AKIHIRO (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1350792-A1 | MEDICINAL COMPOSITIONS IMPROVED IN SOLUBLITY IN WATER | Takeda Chemical Industries, Ltd. (JP) | 2003-10-08 | — | — | EP | disclosed |
| EP-1350793-A1 | MEDICINAL COMPOSITIONS HAVING IMPROVED ABSORBABILITY | Takeda Chemical Industries, Ltd. (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20020173526-A1 | Heterocyclic compounds their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024035-A1 | Heterocyclic compounds, their production and use | ABL1, ROS1, MAPK1 | TSHR 908/4885CA1 2025/4885CA2 972/4885 |
| US-20020173526-A1 | Heterocyclic compounds their production and use | ABL1, ROS1, MAPK1 | TSHR 912/4885CA1 1865/4885CA2 845/4885 |
| US-20040058956-A1 | Pharmaceutical composition having an improved water solubility | ERBB2, EGFR, ABCG2 | TSHR 1790/4885CA1 1778/4885CA2 729/4885 |
| US-20040138160-A1 | Preventive/therapeutic method for cancer | EGFR, ERBB2, ERBB3 | TSHR 694/4885CA1 2468/4885CA2 964/4885 |
| US-20040053972-A1 | Medicinal compositions having improved absorbability | EGFR, ERBB2, ERBB3 | TSHR 2693/4885CA1 674/4885CA2 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.